Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs Solaris Energy Infrastructure Inc. Class A Common Stock (SEI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs Solaris Energy Infrastructure Inc. Class A Common Stock — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.13 (market cap $6.57B), while Solaris Energy Infrastructure Inc. Class A Common Stock trades at $68.5 (market cap $5.12B). The key difference: Iovance Biotherapeutics Inc. Common Stock is the larger of the two by market cap, and Solaris Energy Infrastructure Inc. Class A Common Stock pays a 0.62% dividend while Iovance Biotherapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 1 Days and Solaris Energy Infrastructure Inc. Class A Common Stock for 0 Days on average.
| IOVA | SEI | |
|---|---|---|
Market Cap | $6.57B | $5.12B |
Volume | 11,838,721 | 2,532,496 |
Sector | Health | Energy |
52-Week High | $14.82 | $82.88 |
52-Week Low | $1.81 | $40.64 |
Typical Hold Time | 1 Days | 0 Days |
Enterprise Value | $6.50B | $6.81B |
Dividend Yield | — | 0.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Iovance Biotherapeutics (IOVA) trades at $14.50, down 0.41% on the day, with a bullish technical signal from moving averages. The company shows strong revenue growth, with 2026 guidance raised to $410–420 million, but remains unprofitable with a net income margin of -89.09%. Recent news highlights institutional buying and positive analyst sentiment driven by accelerating adoption of its Amtagvi therapy.
The outlook is optimistic due to expanding TIL therapy applications and raised revenue guidance, but high cash burn and lack of profitability pose significant risks. Analyst consensus is strongly bullish with a $13.44 price target, though the stock faces volatility from clinical trial outcomes and competitive pressures.
SEI (Solaris Energy Infrastructure) trades at $77.83, down 1.83% today, but maintains strong analyst support with 9 unanimous buy ratings and a $100.56 consensus price target. The stock shows positive momentum with three consecutive quarterly earnings beats and projected revenue growth from $622M in 2025 to $762M in 2026. Recent technical analysis indicates neutral signals with support at $76 and resistance at $79.
The outlook remains positive given strong earnings performance and expansion initiatives, though elevated valuation ratios (P/E of 98.52) and significant debt issuance ($1.25B notes) present risks. The upcoming Q3 2026 earnings report on October 21 will be crucial for validating growth trajectory amid energy sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About Solaris Energy Infrastructure Inc. Class A Common Stock
Solaris Energy Infrastructure, Inc. provides mobile power generation, control, and distribution equipment and logistics equipment for managing raw materials at well sites, operating through its Solaris Power Solutions and Solaris Logistics Solutions segments for data center, energy, commercial, and industrial customers.
Read more on SEI →
